Nicolas Azzopardi

911 total citations
24 papers, 625 citations indexed

About

Nicolas Azzopardi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Nicolas Azzopardi has authored 24 papers receiving a total of 625 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Nicolas Azzopardi's work include Monoclonal and Polyclonal Antibodies Research (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Cancer Treatment and Pharmacology (6 papers). Nicolas Azzopardi is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Cancer Treatment and Pharmacology (6 papers). Nicolas Azzopardi collaborates with scholars based in France, United States and Poland. Nicolas Azzopardi's co-authors include Gilles Paintaud, David Ternant, Valérie Gouilleux‐Gruart, Hervé Watier, Nathalie Heuzé‐Vourc'h, Thierry Lecomte, Érick Gamelin, Laurent Guilleminault, J. Montharu and P. Diot and has published in prestigious journals such as The Journal of Immunology, Scientific Reports and Clinical Cancer Research.

In The Last Decade

Nicolas Azzopardi

23 papers receiving 614 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nicolas Azzopardi France 15 215 205 182 159 153 24 625
Seth S. Katz United States 15 195 0.9× 119 0.6× 358 2.0× 108 0.7× 124 0.8× 27 837
Josiah Ryman United States 7 55 0.3× 252 1.2× 172 0.9× 189 1.2× 196 1.3× 11 623
Vladimir Vainstein Israel 15 53 0.2× 112 0.5× 283 1.6× 105 0.7× 226 1.5× 51 723
R L Wolfert United States 9 111 0.5× 85 0.4× 221 1.2× 171 1.1× 131 0.9× 14 578
Philippe Poncelet France 12 54 0.3× 113 0.6× 121 0.7× 279 1.8× 423 2.8× 18 836
Afshin Moradi Iran 14 122 0.6× 35 0.2× 183 1.0× 83 0.5× 216 1.4× 79 640
Shaoqing Ju China 21 82 0.4× 84 0.4× 175 1.0× 148 0.9× 692 4.5× 51 1.1k
Jens Schreiner Germany 15 153 0.7× 130 0.6× 649 3.6× 535 3.4× 204 1.3× 22 1.2k
Cornelis W. Tuk Netherlands 11 51 0.2× 165 0.8× 123 0.7× 421 2.6× 152 1.0× 15 628
Julie Collins United States 11 68 0.3× 64 0.3× 281 1.5× 263 1.7× 119 0.8× 21 578

Countries citing papers authored by Nicolas Azzopardi

Since Specialization
Citations

This map shows the geographic impact of Nicolas Azzopardi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolas Azzopardi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolas Azzopardi more than expected).

Fields of papers citing papers by Nicolas Azzopardi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicolas Azzopardi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolas Azzopardi. The network helps show where Nicolas Azzopardi may publish in the future.

Co-authorship network of co-authors of Nicolas Azzopardi

This figure shows the co-authorship network connecting the top 25 collaborators of Nicolas Azzopardi. A scholar is included among the top collaborators of Nicolas Azzopardi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolas Azzopardi. Nicolas Azzopardi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Lefort, Gaëlle, Thiago S. Nakahara, Nicolas Azzopardi, et al.. (2024). Effect of the social environment on olfaction and social skills in wild-type and a mouse model of autism. Translational Psychiatry. 14(1). 464–464. 4 indexed citations
3.
Paintaud, Gilles, Nicolas Azzopardi, Christophe Passot, et al.. (2023). Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients. Clinical Pharmacokinetics. 62(9). 1263–1274. 1 indexed citations
4.
Caulet, Morgane, Gilles Paintaud, Nicolas Azzopardi, et al.. (2023). Confounding mitigation for the exposure‐response relationship of bevacizumab in colorectal cancer patients. British Journal of Clinical Pharmacology. 90(4). 976–986. 1 indexed citations
5.
Petitcollin, Antoine, Nicolas Azzopardi, Jean‐Yves Pierga, et al.. (2021). Population pharmacokinetics and exposure–response relationship of trastuzumab and bevacizumab in early-stage breast cancer. European Journal of Clinical Pharmacology. 77(12). 1861–1873. 5 indexed citations
6.
Azzopardi, Nicolas, Claire Bonneau, Céline Desvignes, et al.. (2021). Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration. Clinical Pharmacology & Therapeutics. 110(1). 210–219. 7 indexed citations
7.
Azzopardi, Nicolas, Hélène Longuet, David Ternant, et al.. (2021). Relationship Between Antithymocyte Globulin Concentrations and Lymphocyte Sub-Populations in Kidney Transplant Patients. Clinical Pharmacokinetics. 61(1). 111–122. 1 indexed citations
8.
Mulleman, Denis, Gilles Paintaud, Nicolas Azzopardi, et al.. (2019). Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited. Clinical Pharmacokinetics. 59(4). 519–530. 16 indexed citations
9.
Sécher, Thomas, Marion Ferreira, Christelle Parent, et al.. (2019). In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration. Journal of Controlled Release. 303. 24–33. 26 indexed citations
10.
Ternant, David, Nicolas Azzopardi, William Raoul, Théodora Bejan‐Angoulvant, & Gilles Paintaud. (2018). Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans. Clinical Pharmacokinetics. 58(2). 169–187. 28 indexed citations
11.
Gagez, Anne-Laure, Stéphane Leprêtre, Valérie Gouilleux‐Gruart, et al.. (2016). Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. Clinical Pharmacokinetics. 56(6). 635–647. 22 indexed citations
12.
Caulet, Morgane, Thierry Lecomte, Olivier Bouché, et al.. (2016). Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients. Clinical Pharmacokinetics. 55(11). 1381–1394. 49 indexed citations
13.
Pointreau, Y., Nicolas Azzopardi, David Ternant, G. Calais, & Gilles Paintaud. (2016). Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer. Therapeutic Drug Monitoring. 38(5). 567–572. 21 indexed citations
14.
Azzopardi, Nicolas, Sophie Dupuis‐Girod, David Ternant, et al.. (2015). Dose – response relationship of bevacizumab in hereditary hemorrhagic telangiectasia. mAbs. 7(3). 630–637. 16 indexed citations
15.
Rollin, Jérôme, Audrey Payancé, Valérie Gouilleux‐Gruart, et al.. (2015). Significant Effect of VEGFA Polymorphisms on the Clinical Outcome of Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Cetuximab. Pharmacogenomics. 16(18). 2035–2043. 4 indexed citations
16.
Hervé, Virginie, Nathalie Rabbe, Laurent Guilleminault, et al.. (2014). VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. mAbs. 6(6). 1638–1648. 31 indexed citations
17.
Guilleminault, Laurent, Nicolas Azzopardi, Christophe Arnoult, et al.. (2014). Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system. Journal of Controlled Release. 196. 344–354. 95 indexed citations
18.
Passot, Christophe, Nicolas Azzopardi, Sylvaine Renault, et al.. (2013). Influence ofFCGRTgene polymorphisms on pharmacokinetics of therapeutic antibodies. mAbs. 5(4). 614–619. 56 indexed citations
19.
Maillet, A., Laurent Guilleminault, Étienne Lemarié, et al.. (2011). The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors. Pharmaceutical Research. 28(9). 2147–2156. 64 indexed citations
20.
Ternant, David, Danielle Degenne, Nicolas Azzopardi, et al.. (2009). An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Cetuximab. Therapeutic Drug Monitoring. 31(5). 597–601. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Seth S. Katz Breakdown of academic impact, for papers by Josiah Ryman Breakdown of academic impact, for papers by Vladimir Vainstein Breakdown of academic impact, for papers by R L Wolfert Breakdown of academic impact, for papers by Philippe Poncelet Breakdown of academic impact, for papers by Afshin Moradi Breakdown of academic impact, for papers by Shaoqing Ju Breakdown of academic impact, for papers by Jens Schreiner Breakdown of academic impact, for papers by Cornelis W. Tuk Breakdown of academic impact, for papers by Julie Collins
Rankless by CCL
2026